Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Rong Tang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0871-9293; OpenAlex author ID A5045349744. Sources: OpenAlex.

Their work

Papers
22 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2020: 2 papers · 2021: 4 papers · 2022: 3 papers · 2023: 4 papers · 2024: 3 papers · 2025: 2 papers · 2026: 4 papers

Papers 22

  1. Vorinostat Potentiates Chemoimmunotherapy in Immune-Enriched Pancreatic Cancer. Co-author DOI 10.1002/advs.202521844↗
  2. Genomic Alterations and Their Clinical Implications in Pancreatic Ductal Adenocarcinoma in a Large-Scale Chinese Cohort. Co-author DOI 10.1002/cam4.72083↗
  3. Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.05.012↗
  4. Metabolic characterization of the tumor microenvironment orchestrates therapeutic strategies and clinical outcomes in pancreatic cancer. Co-author DOI 10.1038/s41467-026-73702-z↗
  5. The role of the aging process and related factor EMP1 in promoting progression of resectable pancreatic cancer. Co-author DOI 10.1016/j.gendis.2024.101490↗
  6. m6A demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis. Co-author DOI 10.1038/s41419-025-08049-2↗
  7. Integration of single-nucleus and exosome RNA sequencing dissected inter-cellular communication and biomarkers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.csbj.2024.04.021↗
  8. CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/0008-5472.can-23-3596↗
  9. NUSAP1 promotes pancreatic ductal adenocarcinoma progression by drives the epithelial-mesenchymal transition and reduces AMPK phosphorylation. First author DOI 10.1186/s12885-024-11842-5↗
  10. Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogeneity of PET-CT. Co-author DOI 10.1016/j.csbj.2023.04.003↗
  11. Integrated analysis revealed hypoxia signatures and LDHA related to tumor cell dedifferentiation and unfavorable prognosis in pancreatic adenocarcinoma: Hypoxi… First author DOI 10.1016/j.tranon.2023.101692↗
  12. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Co-author DOI 10.1016/j.xcrm.2023.101234↗
  13. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma. First author DOI 10.1136/gutjnl-2022-329349↗
  14. Ferroptosis-related lncRNA pairs to predict the clinical outcome and molecular characteristics of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/bib/bbab388↗
  15. The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2022/4148805↗
  16. Identification of a glycolysis-related gene signature for predicting pancreatic cancer survival. Co-author DOI 10.21037/jgo-22-17↗
  17. Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-021-01900-4↗
  18. Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic rev… Co-author DOI 10.21037/gs-21-16↗
  19. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.648917↗
  20. Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.643465↗
  21. The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer. Co-author DOI 10.21037/atm-20-2554a↗
  22. The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma. Co-author DOI 10.7717/peerj.9602↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 18 shared papers, 2020–2026 · strength 3.10
  2. Si Shi · 17 shared papers, 2020–2026 · strength 2.80
  3. Jin Xu · 15 shared papers, 2020–2026 · strength 2.40
  4. Qingcai Meng · 14 shared papers, 2020–2025 · strength 2.22
  5. Jie Hua · 13 shared papers, 2020–2026 · strength 2.04
  6. Chen Liang · 12 shared papers, 2020–2025 · strength 1.81
  7. Wei Wang · 9 shared papers, 2021–2024 · strength 1.40
  8. Qiong Du · 5 shared papers, 2023–2026 · strength 1.08
  9. Bo Zhang · 6 shared papers, 2020–2024 · strength 0.90
  10. Zeyin Rong · 4 shared papers, 2022–2026 · strength 0.81
  11. Xiaomeng Liu · 5 shared papers, 2021–2025 · strength 0.75
  12. Liquan Jin · 3 shared papers, 2026 · strength 0.72
  13. Yuan Liu · 3 shared papers, 2023–2024 · strength 0.57
  14. Zhen Tan · 3 shared papers, 2023–2025 · strength 0.57
  15. Miaoyan Wei · 2 shared papers, 2026 · strength 0.53
  16. Jiaoshun Chen · 2 shared papers, 2026 · strength 0.48
  17. Chen Chen · 2 shared papers, 2026 · strength 0.48
  18. Mingwei Dong · 2 shared papers, 2023–2026 · strength 0.44
  19. Yiyin Zhang · 3 shared papers, 2020–2023 · strength 0.41
  20. Chenghao Shao · 2 shared papers, 2023–2026 · strength 0.38
  21. Bo Zhang · 2 shared papers, 2022–2024 · strength 0.35
  22. Zijian Wu · 2 shared papers, 2022 · strength 0.34
  23. Ying Liu · 1 shared paper, 2026 · strength 0.27
  24. Xu Jk · 1 shared paper, 2026 · strength 0.27
  25. S. Y. Shi · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.